Muhrer
Gerhard Muhrer, Zurich CH
Patent application number | Description | Published |
---|---|---|
20080306233 | Process for Removing Residual Volatile Monomers from a Polymer in Powder form - A process for purifying a polymer containing residual volatile monomers by drying the polymer powder under vacuum at a pressure and at a temperature which allows the vaporization of the residual monomers and optionally de-aggregating by sieving. | 12-11-2008 |
20090221761 | PROCESS FOR REMOVING RESIDUAL VOLATILE MONOMERS FROM A POLYMER IN POWDER FORM - A process for purifying a polymer containing residual volatile monomers by drying the polymer powder under vacuum at a pressure and at a temperature which allows the vaporization of the residual monomers and optionally de-aggregating by sieving. | 09-03-2009 |
20090264461 | Polymorph of (R)-3- (2-Hydroxy-2, 2-Diphenyl -Acetoxy) -1- (Isoxazol-s-ylcarbamoyl-methyl)-1-Azoni A-Bicyclo-[2.2.2] Octane Bromide - A novel polymorphic crystal form of (R)-3-(2-hydroxy-2,2-diphenyl-acetoxy)-1-(isoxazol-3-ylcarbamoyl-methyl)-1-azonia-bicyclo-[2.2.2]octane bromide, designated crystal form Talpha. Methods for preparing same and the use of the crystal form as the active ingredient of medicaments for the treatment of inflammatory or obstructive airways diseases are also described. | 10-22-2009 |
20100266696 | Organic Compounds - A process of preparing a particulate and substantially crystalline drug substance. The process involves suspending a substantially crystalline drug substance in an anti-solvent to give a suspension, homogenising the suspension at elevated pressure to give drug particles that have a mean particle size of less than about 10 μm, and drying the drug particles to remove any residual anti-solvent. | 10-21-2010 |
Gerhard Muhrer, Basel CH
Patent application number | Description | Published |
---|---|---|
20100247658 | ORGANIC COMPOUNDS - A process for reducing the tendency of a drug substance to aggregate and/or agglomerate during storage. The process involves micronising the drug substance to give a mean particle size of less than about 10 μm, and exposing the micronised drug substance to a dry environment at an elevated temperature between 40° C. and 120° C. for at least six hours. | 09-30-2010 |
Volker Muhrer, Furth DE
Patent application number | Description | Published |
---|---|---|
20130114379 | ATTENUATING MASS FOR AN ULTRASONIC SENSOR, USE OF EPOXY RESIN - Temperature stability at the temperatures prevailing in a motor and stability that is required over an entire temperature range are provided by an attenuating mass. This enables continuous use at temperatures of approximately 150° C. while providing ultrasonic attenuation at low temperatures. | 05-09-2013 |
Volker Muhrer, Fuerth DE
Patent application number | Description | Published |
---|---|---|
20160118175 | CONVERTER UNIT, PARTICULARLY A COMBINATION CONVERTER - A converter unit includes: a housing with a moulded-on hollow cylinder that extends into the housing; a non-magnetic toroidal core supporting a first secondary winding, contacting the housing bottom concentrically with the hollow cylinder and is embedded in a solid compound; a magnetic toroidal core supporting a second secondary winding, arranged concentrically with the hollow cylinder above the non-magnetic toroidal coil; and a casting compound with which the housing opening is closed. To achieve a compact converter unit, a first planar spacing element is arranged between the first and the second secondary windings, directly contacting the first secondary winding and the second secondary winding. In addition, electrically insulating particles fill out the space between the second secondary winding and the housing wall, and the casting compound extends at least up to the particles, which lie at the top towards the housing opening. | 04-28-2016 |